Drug Trial Radar · NCT04009681
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
175
Actual
Start
Jun 20, 2019
Primary completion
Dec 2, 2025
Study completion Dec 2, 2025
Sponsor
- Lead sponsor
- Synthorx, Inc, a Sanofi companyIndustry
- Sponsor type
- Industry
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: * Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G) * Define the Maximium Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and as a combination therapy (Cohorts A, B, C, D, and G) * Evaluate preliminary anti-tumor activity of THOR-707 as a single agent by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohort H only) Secondary Objectives: * Evaluate preliminary anti-tumor activity of THOR-707 as a single agent and as a combination therapy by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohorts A, B, C, D, E, F, and G) * Determine time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and clinical benefit rate (CBR) of THOR-707 as a single agent and as a combination therapy * Evaluate the safety and tolerability of THOR-707 monotherapy QW/Q2W (AE/serious adverse event \[SAE\] profile) (Cohort H only).
Conditions
- Metastasis
Interventions
THOR-707Drug
Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
Checkpoint inhibitorDrug
Pharmaceutical form: solution for IV administration; Route of administration: IV administration
anti-EGFR antibodyDrug
Pharmaceutical form: solution for IV administration; Route of administration: IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Dose-Limiting Toxicities (DLTs)- Cohorts A, B, C, and DTime frame: Study Day 1 up to Day 29
- Maximum Tolerated Dose (MTD)- Cohorts A, B, C, and DTime frame: Study Day 1 up to Day 29
- Recommended Phase 2 Dose (RP2D)- Cohorts A, B, C, and DTime frame: Study Day 1 up to Day 29
- Number of participants with treatment emergent adverse events, serious adverse events, and laboratory abnormalities - Cohorts A, B, C, D, E, F, and GTime frame: Study Day 1 up to approximately 24 months
- Rate of Dose-Limiting Toxicities (DLTs) -Cohort GTime frame: Study Day 1 up to Day 42 (6 week-cycle)
- Recommended Phase 2 Dose (RP2D) of THOR-707- Cohort GTime frame: Study Day 1 up to Day 42 (6 week-cycle)
- Maximum Tolerated Dose (MTD)- Cohort GTime frame: Study Day 1 up to Day 42 (6 week-cycle)
- Objective Response Rate (ORR) according to RECIST version 1.1 -Cohort HTime frame: Study Day 1 up to approximately 24 months
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
Investigational Site Number-1008
Scottsdale, Arizona
Investigational Site Number-1005
Denver, Colorado
Investigational Site Number-1004
Sarasota, Florida
Investigational Site Number-1003
Nashville, Tennessee
Investigational Site Number-1007
Dallas, Texas
Investigational Site Number-1002
Houston, Texas
Investigational Site Number-1001
San Antonio, Texas
Investigational Site Number-7002
Buenos Aires, Argentina
Investigational Site Number-2004
New South Whales, Australia
Investigational Site Number-2001
Perth, Australia
Investigational Site Number-2002
Victoria, Australia
Investigational Site Number-2003
Victoria, Australia
Investigational Site Number- 6001
Santiago, Chile
Investigational Site Number-6002
Santiago, Chile
Investigational Site Number-4002
Singapore, Singapore
Investigational Site-4001
Singapore, Singapore
Investigational Site Number-5001
Barcelona, Spain
Investigational Site Number-5006
Barcelona, Spain
Investigational Site Number-5007
Barcelona, Spain
Investigational Site Number-5002
Madrid, Spain
Investigational Site Number-5003
Madrid, Spain
Investigational Site Number-5004
Madrid, Spain
Investigational Site Number-5005
Madrid, Spain
Investigational Site Number-5105
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.